GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Cash Received from Insurance Activities

Virax Biolabs Group (Virax Biolabs Group) Cash Received from Insurance Activities


View and export this data going back to 2022. Start your Free Trial

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry
Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.